{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:43:07Z","timestamp":1790264587790,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T00:00:00Z","timestamp":1300838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A rapid, sensitive and specific method to quantify cyproheptadine in human plasma using amitriptyline as the internal standard (IS) is described. The analyte and the IS were extracted from plasma by liquid\u2010liquid extraction using a diethyl\u2010ether\/dichloromethane (70\/30; v\/v) solvent. After removing and drying the organic phase, the extracts were reconstituted with a fixed volume of acetonitrile\/water (50\/50 v\/v)\u2009+\u20090.1% of acetic acid. The extracts were analyzed by high performance liquid chromatography coupled to electrospray tandem mass spectrometry (LC\u2010MS\/MS). Chromatography was performed isocratically using an Alltech Prevail C18 5\u2009\u00b5m analytical column, (150\u2009mm\u2009x\u20094.6\u2009mm I.D.). The method had a chromatographic run time of 4\u2009min and a linear calibration curve ranging from 0.05 to 10\u2009ng\/mL (r2\u2009&gt;\u20090.99). The limit of quantification was 0.05\u2009ng\/mL. This HPLC\/MS\/MS procedure was used to assess the bioequivalence of cyproheptadine in two cyproheptadine\u2009+\u2009cobamamide (4\u2009mg\u2009+\u20091\u2009mg) tablet formulations (Cobactin\u00ae [cyproheptadine\u2009+\u2009cobamamide] test formulation supplied from Zambon Laborat\u00f3rios Farmac\u00eauticos Ltda. and Cobavital\u00ae from Solvay Farma (standard reference formulation)). A single 4 mg\u2009+\u20091\u2009mg [cyproheptadine\u2009+\u2009cobamamide] dose of each formulation was administered to healthy volunteers. The study was conducted using an open, randomized, two\u2010period crossover design with a 1\u2010week washout interval. Since the 90% CI for Cmax and AUCs ratios were all within the 80\u2010125% bioequivalence limit proposed by the US Food and Drug Administration, it was concluded that the cyproheptadine test formulation (Cobactin\u00ae) is bioequivalent to the Cobavital\u00ae formulation for both the rate and the extent of absorption of cyproheptadine. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bmc.1618","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T03:29:37Z","timestamp":1300850977000},"page":"129-136","source":"Crossref","is-referenced-by-count":8,"title":["Quantification of cyproheptadine in human plasma by high\u2010performance liquid chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study"],"prefix":"10.1002","volume":"26","author":[{"given":"Gustavo Duarte","family":"Mendes","sequence":"first","affiliation":[{"name":"Department of Pharmacology State University of Campinas  Campinas Brazil"},{"name":"Galeno Research Unit  Campinas Brazil"},{"name":"Faculty of Odontology University Camilo Castelo Branco (UNICASTELO)  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Arruda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology State University of Campinas  Campinas Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Galeno Research Unit  Campinas Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C\u00e1ssio","family":"de Almeida Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Department of Pharmacology State University of Campinas  Campinas Brazil"},{"name":"Faculty of Odontology University Camilo Castelo Branco (UNICASTELO)  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M","family":"Alkharfy","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"De Nucci","sequence":"additional","affiliation":[{"name":"Department of Pharmacology State University of Campinas  Campinas Brazil"},{"name":"Department of Clinical Pharmacy College of Pharmacy King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,23]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"ANVISA\u2010RE 899.2003. Available at:http:\/\/www.anvisa.gov.br\/legis\/resol\/2003\/re\/899_03re.htm"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.200800726"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.06.006"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/jf803395r"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120028749"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2335"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600720925"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)00476-L"},{"key":"e_1_2_7_10_1","first-page":"122","article-title":"Tandem mass spectrometry (LC\u2010MS\u2010MS): a predominant role in bioassays for pharmacokinetic studies","volume":"52","author":"Marzo A","year":"2007","journal-title":"Arzneimittel\u2010Forschung\u2010Drug Research"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1081\/JLC-100101455"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2007.03.111"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj0901005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mas.20046"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.1790"},{"key":"e_1_2_7_16_1","unstructured":"US\u2010FDA Guidance for Industry\u2010Bioanalytical Method Validation.2001."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.1.158"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.02.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2006.03.040"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.1618","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.1618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:39Z","timestamp":1760035419000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.1618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,23]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/bmc.1618"],"URL":"https:\/\/doi.org\/10.1002\/bmc.1618","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,23]]}}}